Literature DB >> 180483

Genetics and the etiology of childhood cancer.

A G Knudson.   

Abstract

A consideration of the world-wide incidences of childhood cancer and of hereditary subgroups leads to the conclusion that two successive mutations can initiate cancer cells and that such cells usually proceed to develop into detectable cancers in a period of time which is short compared with the time required for most adult cancers. Environmental carcinogens could hypothetically increase the rates at which these mutations occur, but they probably, in fact, contribute little to the incidences. Certain exceptions, notably leukemia and lymphoma, are noteworthy, and a viral origin for them has been widely hypothesized. If most solid tumors of childhood are indeed correctly attributable to mutations in germ and/or somatic cells, then the prospect for the prevention of childhood cancer becomes very dim. In fact, the incidence of the germinal forms may increase as treatment improves (18). In theory, one might be able to identify individuals harboring cancer genes germinally and even to identify them prenatally. But even if the burden of cancer attributable to the hereditary subgroups were elimanted, there would still remain the larger nonhereditary group resulting from somatic mutations. If this hypothesis is correct, then childhood cancer cannot be prevented. With this conclusion goes the admonition, however, that environmental mutagens might significantly increase the burden of childhood cancer. One such mutagen, therapeutic radiation, is known to increase the prospect that second tumors will occur in patients who carry a germinal cancer mutation. The major effort to reduce the incidence of childhood cancer by prevention should be spent in examining the possibility that leukemia and lymphoma are viral in origin. If the arguments presented are correct, then the main effort against childhood cancer must be that of early diagnosis and treatment. I realize that many have already argued for that strategy in the approach to cancer generally, but I now believe that it is particularly relevant to any program against cancer in children.

Entities:  

Mesh:

Year:  1976        PMID: 180483     DOI: 10.1203/00006450-197605000-00001

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  Wilms' tumor.

Authors:  R P Warrier; O Regueira
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

Review 2.  Genetics of neoplasia--impact of ecogenetics on oncogenesis. A review.

Authors:  D T Purtilo; L Paquin; T Gindhart
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

3.  Search for somatic DNA variation in the brain: investigation of the serotonin 2A receptor gene.

Authors:  Zachary A Kaminsky; Violeta Popendikyte; Abbas Assadzadeh; Arturas Petronis
Journal:  Mamm Genome       Date:  2005-09-14       Impact factor: 2.957

4.  Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.

Authors:  Nicolas -Xavier Bonne; Rabih Aboukais; Marc Baroncini; Audrey Hochart; Pierre Leblond; Franck Broly; Frédérique Dubrulle; Jean-Paul Lejeune; Christophe Vincent
Journal:  Childs Nerv Syst       Date:  2016-10-04       Impact factor: 1.475

5.  Persistent echoes of the nature-nurture argument.

Authors:  B Childs
Journal:  Am J Hum Genet       Date:  1977-01       Impact factor: 11.025

Review 6.  Molecular diagnostic alterations in squamous cell carcinoma of the head and neck and potential diagnostic applications.

Authors:  Jennifer L Hunt; Leon Barnes; James S Lewis; Magdy E Mahfouz; Pieter J Slootweg; Lester D R Thompson; Antonio Cardesa; Kenneth O Devaney; Douglas R Gnepp; William H Westra; Juan P Rodrigo; Julia A Woolgar; Alessandra Rinaldo; Asterios Triantafyllou; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-07       Impact factor: 2.503

7.  Lack of association between HLA specificities and Wilms' tumour.

Authors:  K G Evers; P Gutjahr; S Zschiedrich; W Haase; U Knoop
Journal:  Eur J Pediatr       Date:  1981-03       Impact factor: 3.183

Review 8.  Progression: the terminal stage in carcinogenesis.

Authors:  H C Pitot
Journal:  Jpn J Cancer Res       Date:  1989-07

9.  High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours.

Authors:  D M Lillington; L K Goff; J E Kingston; Z Onadim; E Price; P Domizio; B D Young
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.